Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article by The Heartland Institute referenced a study published in the December 2012 issue of The American Journal of Managed Care® (AJMC®) titled “Personalized Preventive Care Leads to Significant Reductions in Hospital Utilization.” The study assessed the impact of the MDVIP personalized preventive care model on hospital utilization and found that MDVIP members’ utilization rates were substantially lower than those of nonmembers.
Posted on einnews.com, a press release cited an article published in an August 2017 supplement to AJMC®. The article, “Overview of Atopic Dermatitis,” noted that atopic dermatitis is a multifaceted, chronic relapsing inflammatory skin disease that is the most common skin disease in children, affecting approximately 15% to 20% of children and 1% to 3% of adults.
A piece by pharmiweb.com spotlighted an article published on AJMC.com, the website of AJMC®. The article, “ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit,” noted that while the CAR-T cell therapies isagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may be high in price, a report by ICER finds that the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life-year.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More